Glucose promotes breast cancer aggression and reduces metformin efficacy

Cell Cycle

Volumn 12, Issue 24, 2013, Pages 3759-3769

  Wahdan Alaswad, Reema ^a   Fan, Zeying ^a   Edgerton, Susan M ^a   Liu, Bolin ^a   Deng, Xin Sheng ^b   Arnadottir, Sigrid Salling ^a,c   Richer, Jennifer K ^a   Anderson, Steven M ^a   Thor, Ann D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Breast cancer; Glucose; Metabolism; Metformin; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE; INSULIN GROWTH FACTOR 1 RECEPTOR; METFORMIN; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

AGGRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL MOTILITY; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

BREAST CANCER; GLUCOSE; METABOLISM; METFORMIN; THERAPY;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SIGNAL TRANSDUCTION;

EID: 84891872860     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26641     Document Type: Article

References (59)

1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300:2754-64; PMID:19088353; http://dx.doi.org/10.1001/jama.2008.824
2. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579-91; PMID:15286738; http://dx.doi.org/10.1038/nrc1408
3. Goodwin PJ. Host-related factors in breast cancer: an underappreciated piece of the puzzle? J Clin Oncol 2008; 26:3299-300; PMID:18612145; http://dx.doi.org/10.1200/JCO.2007.15.4526
4. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:88; PMID:19320986; http://dx.doi.org/10.1186/1471-2458-9-88
5. Hall IJ, Newman B, Millikan RC, Moorman PG. Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 2000; 151:754-64; PMID:10965972; http: //dx.doi.org/10.1093/ oxfordjournals.aje.a010275
6. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003; 4:157-73; PMID:12916817; http://dx.doi.org/10. 1046/j.1467-789X.2003.00108.x
7. LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 2008; 116(Suppl 1):S4-6; PMID:18777452; http://dx.doi.org/10.1055/s-2008-1081488
8. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev 2007; 28:763-77; PMID:17981890; http://dx.doi.org/10.1210/er.2006-0019
9. Schapira DV, Kumar NB, Lyman GH, Cox CE. Abdominal obesity and breast cancer risk. Ann Intern Med 1990; 112:182-6; PMID:2297194; http://dx.doi.org/10. 7326/0003-4819-112-3-182
10. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18:598-608; PMID:17046224; http://dx.doi.org/10.1016/j.ceb.2006.10.005
11. Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002; 26:747-53; PMID:12037643
12. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008; 26:3310-6; PMID:18612147; http://dx.doi.org/10.1200/ JCO.2006.10.3168
13. Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol 2008; 26:833-4; PMID:18281653; http://dx.doi.org/10.1200/JCO.2007.14.7132
14. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst 2008; 100:530-2; PMID:18398091; http://dx.doi.org/10.1093/jnci/djn119
15. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008; 109:389-95; PMID:17659440; http://dx.doi.org/10.1007/s10549-007-9654-0
16. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006; 119:236-8; PMID:16450399; http://dx.doi.org/10.1002/ijc.21812
17. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29:40-6; PMID:21115865; http://dx.doi.org/10. 1200/JCO.2009.27.3011
18. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123:627-35; PMID:20571870; http://dx.doi.org/10.1007/s10549-010-0990-0
19. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6:103-11; PMID:15683819; http://dx.doi.org/ 10.1016/S1470-2045(05)01736-5
20. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009; 27:3271-3; PMID:19487373; http://dx.doi.org/10.1200/ JCO.2009.22.1630
21. Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012; 2012:809291; PMID:22295251; http://dx.doi.org/10.1155/2012/809291
22. Guastamacchia E, Resta F, Triggiani V, Liso A, Licchelli B, Ghiyasaldin S, Sabbà C, Tafaro E. Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4:59-66; PMID:15032627; http://dx.doi.org/10.2174/ 1568008043339965
23. Young CD, Anderson SM. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 2008; 10:202; PMID:18304378; http://dx.doi.org/10.1186/bcr1852
24. Goodwin PJ, Ennis M, Bahl M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009; 114:517-25; PMID:18437560; http://dx.doi.org/10.1007/s10549-008-0019-0
25. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al. Phosphorylated insulin-like growth factor-i/ insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68:10238-46; PMID:19074892; http://dx.doi.org/10. 1158/0008-5472.CAN-08-2755
26. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20:42-51; PMID:11773152; http://dx.doi.org/10.1200/JCO.20.1.42
27. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012; 2:778-90; PMID:22926251; http://dx.doi.org/10.1158/2159-8290.CD-12-0263
28. Josefson D. High insulin levels linked to deaths from breast cancer. BMJ 2000; 320:1496; PMID:10834888
29. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760-74; PMID:21084729
30. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118:1202-11; PMID:21800293; http://dx.doi.org/10.1002/cncr.26439
31. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896-917; PMID:22203527
32. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-5; PMID:15849206; http://dx.doi.org/10.1136/bmj.38415.708634.F7
33. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620-5; PMID:19564453; http://dx.doi.org/10.2337/dc08-2175
34. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269-73; PMID:17062558; http://dx.doi.org/10.1158/0008-5472.CAN-06-1500
35. Jiralerspong S, Palla SL, Giordano SH, Meric- Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297-302; PMID:19487376; http://dx.doi.org/10.1200/JCO.2009.19.6410
36. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057-64; PMID:20305377; http://dx.doi.org/10.4161/ cc.9.6.10994
37. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 2006; 29:1990-1; PMID:16873829; http://dx.doi.org/10.2337/dc06-0997
38. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18:54-61; PMID:18387799; http://dx.doi.org/10.1016/j.gde.2008.02.003
39. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33; PMID:19460998; http://dx.doi.org/10.1126/science.1160809
40. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-82; PMID:18538731; http://dx.doi.org/10.1016/j.ccr. 2008.05.005
41. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; http://dx.doi.org/10.1126/science.123.3191.309
42. Zhivotovsky B, Orrenius S. The Warburg Effect returns to the cancer stage. Semin Cancer Biol 2009; 19:1-3; PMID:19162190; http://dx.doi.org/10.1016/ j.semcancer.2008.12.003
43. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005; 23:1664-73; PMID:15755974; http://dx.doi.org/10.1200/JCO. 2005.11.024
44. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209:211-5; PMID:22330683; http://dx.doi.org/10.1084/jem. 20120162
45. Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean PS. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res 2012; 72:6490-501; PMID:23222299; http://dx.doi.org/10.1158/0008-5472.CAN-12-1653
46. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909-15; PMID:19221498; http://dx.doi.org/10.4161/cc.8.6.7933
47. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012; 11:367-76; PMID:22189713; http://dx.doi.org/10.4161/cc.11.2.18813
48. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031-40; PMID:19440038; http://dx.doi.org/10.4161/cc.8.13.8814
49. Menendez JA, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, Joven J, Martin-Castillo B, Vazquez-Martin A. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 2012; 11:2782-92; PMID:22809961; http://dx.doi.org/10.4161/cc.20948
50. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48:R31-43; PMID:22355097; http://dx.doi.org/10.1530/JME-12-0007
51. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012; 29:1314-27; PMID:21301998; http://dx.doi.org/10.1007/ s12032-011-9846-7
52. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-9; PMID:8569826; http://dx.doi.org/10.1056/NEJM199602293340906
53. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135:821-30; PMID:22933030; http://dx.doi.org/10.1007/s10549-012-2223-1
54. Menendez JA, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L, Vazquez-Martin A. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3:1063-77; PMID:22170748
55. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 2013; 110:972-7; PMID:23277563; http://dx.doi.org/10. 1073/pnas.1221055110
56. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807-14; PMID:20890129; http://dx.doi.org/10. 4161/cc.9.18.13131
57. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507-11; PMID:19752085; http://dx.doi.org/10.1158/0008-5472.CAN-09-2994
58. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49(Suppl 2):24S-42S; PMID:18523064; http://dx.doi.org/10.2967/jnumed.107.047258
59. Ding WQ, Liu B, Vaught JL, Palmiter RD, Lind SE. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther 2006; 5:1864-72; PMID:16891473; http://dx.doi.org/10.1158/1535-7163.MCT-06-0067